代谢综合征与胃肠道癌症风险:基于大规模分子数据的调查
研究基于英国生物银行366016名参与者的血清标志物和基因型数据,采用三种定义评估代谢综合征(MetS)与九种胃肠道癌症风险的关联。中位随访7.1年发生4238例 incident 癌症,基线MetS与整体胃肠道癌症风险升高相关(协调定义HR 1.21,95%CI 1.13-1.29),且结直肠癌和胰腺癌的关联不受多基因风险评分分层影响。
要点
- 基线MetS与整体胃肠道癌症风险升高相关(HR 1.21,95%CI 1.13-1.29)。
- MetS与结直肠癌、肝癌、女性胰腺癌及男性食管腺癌风险升高相关。
- 结直肠癌和胰腺癌的关联不受多基因风险评分分层影响(P异质性分别为0.70和0.69)。
核心结论
- 基线代谢综合征与整体胃肠道癌症风险升高相关,且结直肠癌和胰腺癌的关联不受遗传易感性影响。
- 维持良好的代谢健康有助于降低胃肠道癌症负担,无论遗传背景如何。
研究设计与样本
- 研究纳入英国生物银行366016名具有完整血清标志物和基因型数据的参与者。
- 基线时采用三种不同定义判定代谢综合征状态,并在15152名参与者中于中位4.3年后进行重复评估。
- 使用Cox比例风险模型估计癌症结局的多变量风险比和95%置信区间。
- 对结直肠癌和胰腺癌按多基因风险评分进行分层分析。
主要发现
- 中位随访7.1年期间,共发生4238例 incident 胃肠道癌症。
- 基线代谢综合征按任何定义均与整体胃肠道癌症风险升高相关(协调定义HR 1.21,95%CI 1.13-1.29)。
- 代谢综合征与结直肠癌、结肠癌、直肠癌、肝细胞癌、女性胰腺癌和男性食管腺癌风险升高相关。
- 结直肠癌和胰腺癌的关联在多基因风险评分分层间无差异(P异质性分别为0.70和0.69)。
- 基线时患有代谢综合征的参与者中,80%在重复评估时仍保持该状态。
临床怎么用
- 在临床实践中应重视代谢综合征的评估与管理,将其作为胃肠道癌症风险分层和预防的潜在抓手。
- 对于代谢综合征患者,无论遗传风险高低,均应强调维持良好代谢健康以降低胃肠道癌症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome (MetS). However, previous epidemiologic studies lacked full serological biomarker data for the classification of MetS, and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 United Kingdom Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by 3 different definitions at baseline, and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios and 95% confidence intervals for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (hazard ratio, 1.21; 95% confidence interval, 1.13-1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by polygenic risk score strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition.
引用
- Rothwell JA, Jenab M, Karimi M, et al. Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data. Clin Gastroenterol Hepatol. 2021. PMID: 34687971. doi:10.1016/j.cgh.2021.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。